Search research articles
Contact Us
Filters
Showing results (131-140 of 146) with videos related to
Page
of 15
Sort By:
Signal Transduction and Targeted Therapy
|
February 27, 2025
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial
Dan-Yun Ruan, Wen-Wen Huang, Yongsheng Li, et al.
Cancer Communications (London, England)
|
April 2, 2026
Rezivertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study
Sheng Yang, Yanqiu Zhao, Meili Sun, et al.
The Lancet. Respiratory Medicine
|
May 27, 2023
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
Shun Lu, Jianying Zhou, Hong Jian, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 24, 2026
Deulorlatinib (TGRX-326) in ALK gene fusion positive non-small cell lung cancer after failure of second-generation inhibitors (DRAGON): a single-arm, multicenter, phase 2 trial
Jie Huang, Gang Chen, Zhehai Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 1, 2022
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study
Yuankai Shi, Shiman Wu, Ke Wang, et al.
Nature Medicine
|
January 6, 2025
Glecirasib in KRAS<sup>G12C</sup>-mutated nonsmall-cell lung cancer: a phase 2b trial
Yuankai Shi, Jian Fang, Ligang Xing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet, et al.
The Lancet. Respiratory Medicine
|
February 6, 2025
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
Yuankai Shi, Yanzhen Guo, Xingya Li, et al.
Lancet (London, England)
|
May 31, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
Shun Lu, Baogang Liu, Yongzhong Luo, et al.
Lancet (London, England)
|
October 22, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
Zhiwei Chen, Fang Yang, Zhou Jiang, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 146) with videos related to
Sort By:
Page
of 15
Signal Transduction and Targeted Therapy
|
February 27, 2025
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial
Dan-Yun Ruan, Wen-Wen Huang, Yongsheng Li, et al.
Cancer Communications (London, England)
|
April 2, 2026
Rezivertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study
Sheng Yang, Yanqiu Zhao, Meili Sun, et al.
The Lancet. Respiratory Medicine
|
May 27, 2023
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
Shun Lu, Jianying Zhou, Hong Jian, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 24, 2026
Deulorlatinib (TGRX-326) in ALK gene fusion positive non-small cell lung cancer after failure of second-generation inhibitors (DRAGON): a single-arm, multicenter, phase 2 trial
Jie Huang, Gang Chen, Zhehai Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 1, 2022
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study
Yuankai Shi, Shiman Wu, Ke Wang, et al.
Nature Medicine
|
January 6, 2025
Glecirasib in KRAS<sup>G12C</sup>-mutated nonsmall-cell lung cancer: a phase 2b trial
Yuankai Shi, Jian Fang, Ligang Xing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet, et al.
The Lancet. Respiratory Medicine
|
February 6, 2025
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
Yuankai Shi, Yanzhen Guo, Xingya Li, et al.
Lancet (London, England)
|
May 31, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
Shun Lu, Baogang Liu, Yongzhong Luo, et al.
Lancet (London, England)
|
October 22, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
Zhiwei Chen, Fang Yang, Zhou Jiang, et al.
Page
of 15